Patents by Inventor Jun Yeul LIM

Jun Yeul LIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATION OF MODIFIED INTERLEUKIN-7 FUSION PROTEIN
    Publication number: 20250257109
    Abstract: Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5w/v %; and (d) a surfactant with a concentration of 0.05 to 6w/v %. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.
    Type: Application
    Filed: January 17, 2025
    Publication date: August 14, 2025
    Applicant: Genexine, Inc.
    Inventors: Donghoon CHOI, Changyong EUN, Seong Hoon JEONG, Jun Yeul LIM
  • Formulation of modified interleukin-7 fusion protein
    Patent number: 12344647
    Abstract: Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v %; and (d) a surfactant with a concentration of 0.05 to 6 w/v %. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: July 1, 2025
    Assignee: Genexine, Inc.
    Inventors: Donghoon Choi, Changyong Eun, Seong Hoon Jeong, Jun Yeul Lim
  • FORMULATION OF MODIFIED INTERLEUKIN-7 FUSION PROTEIN
    Publication number: 20230279069
    Abstract: Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v%; and (d) a surfactant with a concentration of 0.05 to 6 w/v%. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.
    Type: Application
    Filed: November 8, 2022
    Publication date: September 7, 2023
    Applicant: Genexine, Inc.
    Inventors: Donghoon CHOI, Changyong Eun, Seong Hoon Jeong, Jun Yeul LIM
  • Formulation of modified interleukin-7 fusion protein
    Patent number: 11548927
    Abstract: Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v %; and (d) a surfactant with a concentration of 0.05 to 6 w/v %. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 10, 2023
    Assignee: GENEXINE, INC.
    Inventors: Donghoon Choi, Changyong Eun, Seong Hoon Jeong, Jun Yeul Lim
  • FORMULATION OF MODIFIED INTERLEUKIN-7 FUSION PROTEIN
    Publication number: 20180327472
    Abstract: Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v %; and (d) a surfactant with a concentration of 0.05 to 6 w/v %. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 15, 2018
    Applicant: GENEXINE, INC.
    Inventors: Donghoon CHOI, Changyong EUN, Seong Hoon JEONG, Jun Yeul LIM